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Available online 8 July 2019Objective: To evaluate activity and safety of obinutuzumab-miniCHOP (Ga101-miniCHOP) combination in older
patients with Diffuse Large B-Cell Lymphoma (DLBCL) unfit to receive full dose immunochemotherapy.
Materials and Methods:We conducted a Simon's two-stage phase II multicenter trial to investigate response rate
(primary endpoint) and safety of six courses of Ga101-miniCHOP in older patients with DLBCL (≥65 years), pro-
spectively defined as unfit according to a simplified Comprehensive Geriatric Assessment (sCGA).
Results:Overall, 34 patients were enrolled (median age 82 years; range 68–89), with 27 out of the 33 eligible pa-
tients completing all six planned courses. Complete Remission (CR) rate was reported in fourteen patients (42%).
After a median follow-up of sixteen months, the two-year Progression Free and Overall Survival (PFS and OS)
were 49% (95% Confidence Interval (CI), 28 to 67) and 68% (95% CI, 49 to 81), respectively. The most frequent
grade 3–4 adverse event was neutropenia in thirteen patients (26%).
Conclusions:Based on the observed CR rate, study accrualwas interrupted due to the very lowprobability of dem-
onstrating the initial study hypothesis that Ga101-miniCHOP could improve results of historical data obtained
with R-miniCHOP in this group of patients. Nonetheless, results achieved with the 33 treated patients confirm
activity and good tolerability of the Ga101-miniCHOP regimen for older unfit adult patients with DLBCL.
© 2019 Published by Elsevier Ltd.Keywords:





Obinutuzumab-miniCHOPle S.Maria Nuova, Azienda Unità
80, 42123 Reggio Emilia, Italy.1. Introduction
Treatment of very old or unfit patients with Diffuse Large B-Cell
Lymphoma (DLBCL) is challenging due to the presence of comorbidities
or concomitant medical or physical conditions which are frequent in
elderly patients and which limit available therapeutic options. Combi-
nation of rituximab with full dose CHOP (cyclophosphamide,
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disputed standard treatment for all patients, including elderly
subjects, but it is not usually prescribed in patients who are
older than 80 years or in those who are not fit enough to receive
full dose chemotherapy. An attenuated version of R-CHOP, namely
R-miniCHOP, has been recommended as standard regimen for pa-
tients older than 80 years based on the positive results of a large
phase II study [1,2]. Obinutuzumab (Ga101) is a glycoengineered,
type II anti-CD20 monoclonal antibody with greater direct cell
death induction and antibody-dependent cellular cytotoxicity
and phagocytosis than rituximab [3]. In parallel with the identifi-
cation of the most active immunochemotherapy regimen similar
efforts are required to grant for an accurate and objective pre-
treatment selection of the older patient with DBLCL in order to
optimize risk to benefit ratio of treatment. We conducted a pro-
spective phase II study (FIL_GAEL Study; ClinicalTrials.gov Identi-
fier: NCT02495454) to evaluate activity and safety of Ga101-
miniCHOP combination in older patients with DLBCL who were
prospectively defined as unfit according to a simplified Compre-
hensive Geriatric Assessment (sCGA) [4].Table 1




Age Median (range) 82 (68–89)
≥80 years 23 70
Gender Male 19 55
Stage III-IV 27 81
ECOG PS 2 2 6
LDH NUNL 23 70
IPI 3–5 21 64
Geriatric assessment
Unfit patients for age 23 70
ADL = 5 6 18
IADL = 7–6 1 3
ADL + IADL 2 6
CIRS grade-2 comorbidities (N = 5–8) 1 3
Cardiac comorbidity grade 1–2 18 54
Treatment activity and survival
Response CR rate 14 42
PR rate 8 24
SD/PD 10 30
Not evaluable 1 3
2-year PFS % (95% CI) 49% (28 to 67)
2-year OS % (95% CI) 68% (49 to 81)
ECOG PS, Eastern Cooperative Oncology Group Performance Status; LDH, lactate dehydro-
genase; IPI, International Prognostic Index; ADL, Activity of Daily Living; IADL, Instrumen-
tal Activity of Daily Living (IADL), CIRS-G, Cumulative Illness Rating Scale – Geriatric; CR,
Complete Remission; PR, Partial Remission; SD, Stable Disease; PD, Progressive Disease;
PFS, Progression Free Survival; OS, Overall Survival; CI, Confidence Interval.2. Methods
The study was approved by local Ethics Committee and Institutional
Review Board of each participating centres and registered on
ClinicalTrials.gov with number NCT02495454.
Older adults (≥65 years) with a newly diagnosed DLBCL were
considered eligible if they were unfit on the sCGA. Simplified CGA
was performed during staging procedures, after written informed
consent, through application of the following instruments: comor-
bidity score according to the Cumulative Illness Rating Scale for Ge-
riatrics (CIRS-G) [5]; the Index of Independence in Activities of
Daily Living (ADL) [6]; the Instrumental Activity of Daily Living
(IADL) scale [7].
Patients were classified as unfit with different criteria according to
age: for patients aged ≥80 years old; no limitations in ADL and IADL
scores, no grade 3–4 comorbidities and less than five grade 2 comorbid-
ities at CIRS-Gwere required. Patients younger than 80 years were clas-
sified as unfit with a at least one of the following; ADL score of 5, IADL
score of 6–7, 5 to 8 grade-2 comorbidities without any grade 3–4 co-
morbidity at CIRS-G [4]. Frail patients, as per Tucci et al., [4] and patients
with transformed lymphoma were excluded.
Patients received miniCHOP (400 mg/m2 cyclophosphamide,
25 mg/m2 doxorubicin, 1 mg vincristine on day 1 of each cycle, and
40 mg/m2 prednisone on days 1–5 every 21 days), combined with
obinutuzumab 1000 mg on days 1,8, and 15 of cycle one, and on day 1
of subsequent cycles. Treatment plan consisted of six cycles of Ga101-
miniCHOP followed by two additional doses of Ga101, every 21 days.
The use of G-CSF was mandatory.
The primary endpoint was Complete Response Rate (CRR) ac-
cording to Cheson 1999 criteria [8]. Secondary endpoints included
assessment of adverse events (AE), response rate according to
Cheson 2007 criteria [9], Overall Response Rate (ORR), Overall
Survival (OS), and Progression-Free Survival (PFS). The sample
size was estimated according to Simon's optimal two-stage
design. The study was designed to assess whether Ga101-
miniCHOP could increase the CRR compared to historical data.
The null hypothesis (p0) was set at 0.60 on the basis of Peyrade
et al.'s findings [1] and the alternative hypothesis (p1) was set
at 0.75, with type I and II errors of 10% and 90%. A total of 71 pa-
tients were required, with at least 48 in complete remission (CR),
to draw a conclusion on the efficacy of treatment. The second
stage could be activated with at least 22 CR out of the first 34 pa-
tients. Analysis was by intention to treat. Here we report the re-
sults of the first stage.3. Results and Discussion
From August 2015 to June 2016, 34 patients were enrolled by
sixteen Italian centers: one patient was subsequently excluded
due to violation of inclusion criteria (Richter syndrome) (Table 1).
Overall, 228 cycles were delivered, with 27/33 patients completing
all six planned courses; four patients interrupted treatment be-
cause of AEs and two because of lack of response. Adverse events
that caused treatment interruption included infection in two
cases, hepatic toxicity and worsening of performance status in
one case each. Treatment delays were reported in 34 out of 228 de-
livered cycles and were evenly distributed among cycles. Final re-
sponse was reported as complete in fourteen patients (42%), and
partial in eight (24%); ten patients had stable or progressive dis-
ease (30%) and one patient (3%) was not assessed for response. 2-
fluoro-2-deossi-D-glucose Positron Emission Tomography (FDG-
PET) was used in 25 patients to define response; complete meta-
bolic response was observed in seventeen cases. Thirty-three pa-
tients experienced AEs (details are provided in Table 2). An
adverse event leading to death was reported in one patient (heart
failure in a patient in CR five months after the last dose of
chemotherapy).
After amedian follow-up of sixteenmonths, eighteen patients expe-
rienced lymphoma progression, one relapsed, and ten died (nine due to
lymphoma progression, and one due to AE during follow up in CR). The
two-year PFS and OS were 49% (95% Confidence interval (CI), 28 to 67)
and 68% (95% CI 49 to 81), respectively. Based on the observed CR rate,
study accrualwas interrupted due to the very lowprobability of demon-
strating the initial study hypothesis that Ga101-miniCHOP could im-
prove results of historical data obtained with R-miniCHOP in this
group of patients. Nonetheless, results achieved with the 33 treated pa-
tients in first stage are available to confirm activity and good tolerability
of the Ga101-miniCHOP regimen for older unfit patients affected by
DLBCL.
These results are consistent with those from the recently pub-
lished randomized Goya trial [10], which compared Ga101-CHOP
Table 2
Summary of hematological and extra-hematological adverse events.
Adverse event (N = 33) Grade 1–2 Grade 3–4
N % N %
Hematological
Anemia 6 18 – –
Leucopenia 2 6 2 6
Neutropenia 2 6 13 26
Thrombocytopenia 10 30 1 3
Extra-hematological
Cardiac disorders 3 9 2 6
Gastrointestinal disorders 11 33 1 3
Hepatobiliary disorders – – 2 6
General disorders 4 12 2 6
Infections and infestations 6 18 1 3
Injury/poisoning/
Procedural complications – – 2 6
Investigations 2 6 1 3
Metabolism and nutrition disorders 5 15 3 9
Musculoskeletal - connective tissue dis. 5 15 3 6
Neoplasms benign, malignant and unspec. – – 2 6
Nervous system disorders - psychiatric dis. 6 18 1 3
Renal and urinary disorders 2 6 – –
Respiratory/thoracic and mediastinal 5 15 – –
Vascular 1 3 – –
Other 8 24
Legend to table: dis, disease; unspec, unspecified.
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and which was not able to demonstrate superiority of Ga101 chemo-
therapy. The Goya results and those from our small study suggest
that the increase in treatment efficacy in DLBCL likely cannot be
achieved by potentiating the anti-CD20 monoclonal antibody part
of therapy. This observation is also confirmed by the results of a
phase II study where rituximab was substituted with ofatumumab,
another second generation anti-CD20 antibody, and combined with
mini-CHOP in 120 DLBCL patients older than 80 years [11]. Although
a formal comparison between the two phase II studies is not appro-
priate, Peyrade et al. achieved similar results with ofatumumab
(Ofa) or rituximab combined with miniCHOP, and the greatest im-
provement in the Ofa-miniCHOP study was likely an effect of the
adoption of a mandatory pre-phase therapy with steroids and vin-
cristine that actually reduced the rate of early fatal events.
Regarding the prospective use of sCGA this work is part of a
larger project for older patients with DLBCL for whom a prelimi-
nary sCGA is required to define patient fitness status and to adapt
treatment goals. This project is conducted by the FIL (Fondazione
Italiana Linfomi) as an observational study (NCT02364050), with
about 1400 enrolled patients with the aim to validate the use of
sCGA and to define separate groups of patients to enroll into dedi-
cated clinical trials. Patients prospectively enrolled in this so-called
“Elderly Project” were categorized into one of three groups namely
FIT, UNFIT and FRAIL. FIT patients were then offered a standard R-
CHOP treatment or clinical trials with curative intent; UNFIT pa-
tients were better candidates for adapted R-CHOP regimens, or to
dedicated clinical trials, like the Ga101-miniCHOP used in this
trial. Finally FRAIL patients were offered low toxic regimens or clin-
ical trials with palliative intent. To the best of our knowledge the
elderly project is the first attempt to try to objectify and standard-
ize treatment choices and goals of older patients with DLBCL and to
better approach clinical research in this population.
4. Conclusions
In conclusion, our phase II study confirmed the activity and safety of
Ga101-miniCHOP for the treatment of older, unfit patients with DLBCL,
but was not able to show it as a promising regimen to challenge the
current standard R-miniCHOP. To improve treatment efficacy in thishard-to-treat patient population, different strategies should be adopted
that include better patient and/or lymphoma profiling and the use of
new drugs with a novel non-cross-resistant mechanism of action.
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